Toremifene and its metabolites enhance doxorubicin accumulation in estrogen receptor negative multidrug resistant human breast cancer cells Valerie WiebeSteven KoesterMichael DeGregorio Preclinical Studies Pages: 63 - 71
Evaluation ofin vitro drug screening leads using experimental models of human ovarian cancer Karen G. LouieThomas C. HamiltonRobert F. Ozols Preclinical Studies Pages: 73 - 78
Bis-daunomycin hydrazones: Interactions with DNA Don R. PhillipsRobert T. C. BrownleePanayiotis A. Scourides Preclinical Studies Pages: 79 - 88
Phase II trial of 5 day continuous intravenous infusion of 6-thioguanine in patients with recurrent and metastatic squamous cell carcinoma of the head and neck Flavio KruterMario EisenbergerSteven Krasnow Clinical Studies Pages: 89 - 91
Evaluation of CHIP (iproplatin) in recurrent pediatric malignant solid tumors Ruprecht NitschkeCharles PrattStuart Toledano Clinical Studies Pages: 93 - 96
Oral piritrexim — A phase II study in patients with advanced soft tissue sarcoma Judith D. SchieselMatthew CarabasiRichard V. Smalley Clinical Studies Pages: 97 - 98
Phase II study of amonafide in advanced and recurrent sarcoma patients Raymond P. PerezSherri L. NashPeter J. O'Dwyer Clinical Studies Pages: 99 - 101
Menogaril in the treatment of malignant mesothelioma: A phase II study C. A. HudisD. P. Kelsen Clinical Studies Pages: 103 - 106
A phase II study of crisnatol mesylate in patients with ovarian carcinoma Richard V. SmalleyDavid GoldsteinRichard L. Tuttle Clinical Studies Pages: 107 - 112
Phase II clinical and pharmacological study of didemnin B in patients with metastatic breast cancer John A. BenvenutoRobert A. NewmanRonald S. Walters Clinical Studies Pages: 113 - 117
Phase II clinical study of pirarubicin in hormone resistant prostate cancer Bernardo Leon RapoportGeoffrey Falkson Clinical Studies Pages: 119 - 121
Phase II feasibility study of high dose epirubicin plus etoposide and cisplatin (HDEEC) regimen in small cell lung cancer Rafael RosellJuan CarlesNassir Haboubi Clinical Studies Pages: 123 - 128
Phase II evaluation of piroxantrone in renal cell carcinoma Ace AllenMichael WolfMargaret L. Barnett Clinical Studies Pages: 129 - 132